Merck & Co., Inc. $MRK Shares Sold by Carlton Hofferkamp & Jenks Wealth Management LLC

Carlton Hofferkamp & Jenks Wealth Management LLC reduced its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 11,958 shares of the company’s stock after selling 392 shares during the period. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $978,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legend Financial Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. during the second quarter valued at $25,000. Barnes Dennig Private Wealth Management LLC acquired a new stake in Merck & Co., Inc. in the 1st quarter worth about $27,000. CBIZ Investment Advisory Services LLC grew its holdings in Merck & Co., Inc. by 141.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after purchasing an additional 221 shares during the period. MorganRosel Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the 1st quarter valued at $36,000. Finally, Advantage Trust Co increased its holdings in shares of Merck & Co., Inc. by 57.1% during the 2nd quarter. Advantage Trust Co now owns 550 shares of the company’s stock worth $44,000 after buying an additional 200 shares during the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

MRK stock opened at $87.54 on Friday. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $106.49. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $218.65 billion, a PE ratio of 13.49, a P/E/G ratio of 0.96 and a beta of 0.37. The firm has a 50-day moving average of $84.43 and a two-hundred day moving average of $81.54.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, topping the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on MRK. Wells Fargo & Company reduced their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 30th. Morgan Stanley decreased their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a report on Thursday, July 10th. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Monday, October 13th. They issued a “neutral” rating and a $95.00 price target for the company. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $104.33.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.